{
    "nct_id": "NCT06623409",
    "official_title": "A Phase 1, Randomized, Double-Blind, Comparator-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity of V540B in Healthy Adults.",
    "inclusion_criteria": "The key inclusion criteria include but are not limited to the following:\n\n* Is in good health based on medical history, physical examination, vital sign (VS) measurements and electrocardiograms (ECGs) performed before randomization.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 45 Years",
    "exclusion_criteria": "The key exclusion criteria include but are not limited to the following:\n\n* Has a history of abnormal Pap smears, HPV- related external genital lesions (eg,condyloma acuminate, vulval intraepithelial neoplasia (VIN), or prostatic intraepithelial neoplasia (PIN)) or external genital cancer (eg, penile cancer), HPV-related vaginal or anal lesions (eg, condyloma acuminata or vaginal intraepithelial neoplasia (VaIN)) or vaginal or anal cancer.\n* Has a history of cancer (malignancy).\n* Has received any HPV vaccine or is expected to receive any HPV vaccine during the study, outside the protocol.",
    "miscellaneous_criteria": ""
}